{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Unicycive Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"UNCY"},"Address":{"label":"Address","value":"5150 EL CAMINO REAL,SUITE A-32 SUITE 210, LOS ALTOS, California, 94022, United States"},"Phone":{"label":"Phone","value":"+1 650 351-4495"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury."},"CompanyUrl":{"label":"Company Url","value":"https://www.unicycive.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Guru Reddy","title":"Vice President-Preclinical R & D"},{"name":"Pramod K. Gupta","title":"Executive VP-Pharmaceutical & Business Operations"},{"name":"Shalabh Gupta","title":"Chairman, President & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}